Suggested Readings

Heartburn and Acid Reflux Cure Program

New Heartburn Cure

Get Instant Access

Arguedas MR, Eloubeidi MA. Barrett's oesophagus: a review of costs of the illness. Pharmacoeconomics 2001;19:1003-1011.

Barrett MT, Sanchez CA, Prevo LJ, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999;22:106-109.

Benipal P, Garewal HS, Sampliner RE, et al. Short segment Barrett's esophagus: relationship of age with extent of intestinal metaplasia. Am J Gastroenterol 2001; 96:3084-3088.

Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-1289.

Buttar NS, Wang KK, Anderson MA, et al. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J Natl Cancer Inst 2002a;94:422-429.

Buttar NS, Wang KK, Leontovich O, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002b;122:1101-1112.

Buttar NS, Wang KK, Lutzke LS, Krishnadath KK, Anderson MA. Combined endo-scopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus. Gastrointest Endosc 2001a;54:682-688.

Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001b;120: 1630-1639.

Cameron AJ. Barrett's esophagus: prevalence and size of hiatal hernia. Am J Gastroenterol 1999;94:2054-2059.

Cameron AJ, Carpenter HA. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study. Am J Gastroenterol 1997;92:586-591.

Cameron AJ, Lagergren J, Henriksson C, et al. Gastroesophageal reflux disease in monozygotic and dizygotic twins. Gastroenterology 2002a;122:55-59.

Cameron AJ, Lomboy CT. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 1992;103:1241-1245.

Cameron AJ, Lomboy CT, Pera M, Carpenter HA. Adenocarcinoma of the esoph-agogastric junction and Barrett's esophagus. Gastroenterology 1995;109:1541-1546.

Cameron AJ, Souto EO, Smyrk TC. Small adenocarcinomas of the esophagogastric junction: association with intestinal metaplasia and dysplasia. Am J Gastroen-terol 2002b;97:1375-1380.

Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990;99:918-922.

Canto MI, Setrakian S, Petras RE, et al. Methylene blue selectively stains intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc 1996;44:1-7.

Canto MI, Setrakian S, Willis J, et al. Methylene blue directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett's esophagus. Gas-trointest Endosc 2000;51:560-568.

Castell DO. Aggressive acid control: minimizing progression of Barrett's esophagus. Am J Manag Care 2001;7:S15-S18.

Chalasani N, Wo JM, Hunter JG, et al. Significance of intestinal metaplasia in different areas of esophagus including esophagogastric junction. Dig Dis Res 1997;42:603-607.

Champion G, Richter JE, Vaezi MF, Singh S, Alexander R. Duodenogastro-esophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology 1994;107:747-754.

Chow WC, Finkle WD, McLaughlin JK, Frankl H, Ziel HK. The relation of gas-troesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995;274:474-477.

Clark GW, Ireland AP, DeMeester TR. Dysplasia in Barrett's esophagus: diagnosis, surveillance and treatment. Dig Dis 1996;14:213-227.

Clark GW, Smyrk TC, Budiles P, et al. Barrett's metaplasia the source of adenocarcinomas of the cardia? Arch Surg 1994;129:609-614.

Conio M, Cameron AJ, Romero Y, et al. Secular trends in the epidemiology and outcome of Barrett's esophagus in Olmsted County, Minnesota. Gut 2001;48: 304-309.

Cooper BT, Neumann CS, Cox MA, Iqbal TH. Continuous treatment with omepra-zole 20 mg daily for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther 1998;12:893-897.

Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003;124:47-56.

Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002; 122:633-640.

Cossentino MJ, Wong RK. Barrett's esophagus and risk of esophageal adenocarcinoma. Semin Gastrointest Dis 2003;14:128-135.

DeVault KR. Epidemiology and significance of Barrett's esophagus. Dig Dis 2000; 18:195-202.

Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-2053.

Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997;92:212-215.

Eckardt VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. Am J Med 2001; 111:33-37.

Ell C, May A, Gossner L, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 2000;118:670-677.

Endlicher E, Knuchel R, Messmann H. [Surveillance of patients with Barrett's esophagus]. Z Gastroenterol 2001;39:593-600.

Ertan A, Younes M. Barrett's esophagus. Dig Dis Sci 2000;45:1670-1673.

Falk GW. Barrett's esophagus. Gastroenterology 2002;122:1569-1591.

Falk GW. Gastroesophageal reflux disease and Barrett's esophagus. Endoscopy 2001;33:109-118.

Falk GW. Reflux disease and Barrett's esophagus. Endoscopy 1999;31:9-16.

Farrow D, Vaughn T, Hansen P, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998;7:49-102.

Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 1996;98:2120-2128.

Gadour M, Ayoola EA. Barrett's esophagus: a review. Trop Gastroenterol 2002;23: 157-161.

Garewal HS, Gerner EW, Sampliner RE, Roe D. Ornithine decarboxylase and polyamine levels in columnar upper gastrointestinal mucosae in patients with Barrett's esophagus. Cancer Res 1988;48:3288-3291.

Garewal HS, Sampliner RE, Fennerty MB. Chemopreventive studies in Barrett's esophagus: a model premalignant lesion for esophageal adenocarcinoma. J Natl Cancer Inst Monogr 1992:51-54.

Gerner EW, Garewal HS, Emerson SS, Sampliner RE. Gastrointestinal tissue polyamine contents of patients with Barrett's esophagus treated with alpha-difluoromethylornithine. Cancer Epidemiol Biomarkers Prev 1994;3:325-330.

Giard RW, Coebergh JW, Ouwendijk RJ. [Revision needed of follow-up policy for Barrett's esophagus]. Ned Tijdschr Geneeskd 2002;146:150-154.

Gillen P, McDermott M, Grehan D, Hourihane DO, Hennessy TP. Proliferating cell nuclear antigen in the assessment of Barrett's mucosa. Br J Surg 1994;81:1766-1768.

Grade AJ, Shah IA, Medlin SM, Ramirez FC. The efficacy and safety of argon plasma coagulation therapy in Barrett's esophagus. Gastrointest Endosc 1999; 50:18-22.

Gulizia JM, Wang H, Antonioli D, et al. Proliferative characteristics of intes-tinalized mucosa in the distal esophagus and gastroesophageal junction (short-segment Barrett's esophagus): a case control study. Hum Pathol 1999;30: 412-418.

Haag S, Nandurkar S, Talley N. Regression of Barrett's esophagus: the role of acid suppression, surgery and ablative methods. Gastrointest Endosc 1999;50:229-240.

Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994; 25:982-993.

Haggitt RC, Reid BJ, Rabinovitch PS, Rubin CE. Barrett's esophagus. Correlation between mucin histochemistry, flow cytometry, and histologic diagnosis for predicting increased cancer risk. Am J Pathol 1988;131:53-61.

Haggitt RC, Tryzelaar J, Ellis FH, et al. Adenocarcinoma complicating columnar epithelial lined (Barrett's) esophagus. Am J Clin Pathol 1978;70:1-5.

Heitmiller RF, Redmond M, Hamilton SR. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Ann Surg 1996;224: 66-71.

Hong MK, Laskin WB, Herman BE, et al. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia of Barrett's esophagus. Cancer 1995;75:423-429.

Inadomi JM, Sampliner R, Lagergren J, et al. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003;138: 176-186.

Kaur BS, Khamnehei N, Iravani M, et al. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 2002;123:60-67.

Khan S, Do KA, Kuhnert P, et al. Diagnostic value of p53 immunohistochemistry in Barrett's esophagus: an endoscopic study. Pathology 1998;30:136-140.

Klaus A, Hinder RA. Indications for antireflux surgery in Barrett's. Semin Laparosc Surg 2001;8:234-239.

Klaus A, Hinder RA. Medical therapy versus antireflux surgery in Barrett's esophagus: what is the best therapeutic approach? Dig Dis 2000;18:224-231.

Krishnadath KK, Wang KK, Taniguchi K, et al. Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. Gastroenterology 2000;119:624-630.

Kulke MH, Thakore KS, Thomas G, et al. Microsatellite instability and hMLH1/hMSH2 expression in Barrett esophagus-associated adenocarcinoma. Cancer 2001;91:1451-1457.

Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340:825-831.

Langman M, Cheng K, Gilman E, et al. Effect of anti-inflammatory drugs on overall risk of common cancer: case control study in general practice research database. BMJ 2000;320:1642-1646.

Leung WK, Sung JJ. Review article: intestinal metaplasia and gastric carcinogene-sis. Aliment Pharmacol Ther 2002;16:1209-1216.

May A, Gossner L, Behrens A, et al. A prospective randomized trial of two different endoscopic resection techniques for early stage cancer of the esophagus. Gastrointest Endosc 2003;58:167-175.

May A, Gossner L, Pech O, et al. Local endoscopic therapy for intraepithelial highgrade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol 2002;14:1085-1091.

Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett's esophagus: a reaffirmation. Hum Pathol 2001;32:368-378.

Morales TG, Sampliner RE, Bhattacharyya A. Intestinal metaplasia of the gastric cardia. Am J Gastroenterol 1997;92:414-418.

Neshat K, Sanchez CA, Galipeau PC, et al. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology 1994;106:1589-1595.

Ormsby AH, Goldblum JR, Rice TW, Richter JE, Gramlich TL. The utility of cyto-keratin subsets in distinguishing Barrett's-related oesophageal adenocarcinoma from gastric adenocarcinoma. Histopathology 2001;38:307-311.

Ortiz-Hidalgo C, De La Vega G, Aguirre-Garcia J. The histopathology and biologic prognostic factors of Barrett's esophagus: a review. J Clin Gastroenterol 1998;26: 324-333.

Overholt BF. Acid suppression and reepithelialization after ablation of Barrett's esophagus. Dig Dis 2000a;18:232-239.

Overholt BF. Evaluating treatments of Barrett's esophagus that shows high-grade dysplasia. Am J Manag Care 2000b;6:S903-S908.

Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gas-trointest Endosc 2003;58:183-188.

Pacifico RJ, Wang KK. Role of mucosal ablative therapy in the treatment of the columnar-lined esophagus. Chest Surg Clin N Am 2002;12:185-203.

Paraf F, Flejou JF, Pignon JP, et al. Surgical pathology of adenocarcinoma arising in Barrett's esophagus. Am J Surg Pathol 1995;19:183-191.

Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993;104:510-513.

Peters JH, Clark GWB, Ireland AP, et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994;108:811-822.

Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gas-troenterol 2001;96:3071-3083.

Reid BJ. Barrett's esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am 1991;20:817-834.

Reid BJ, Blount PL, Feng Z, Levine DS. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol 2000a;95: 3089-3096.

Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dys-plasia in Barrett's esophagus. Hum Pathol 1988;19:166-178.

Reid B, Levine D, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low and high risk patient subsets. Am J Gastroenterol 2000b;95:1669-1679.

Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001;96:2839-2848.

Richter JE. Importance of bile reflux in Barrett's esophagus. Dig Dis 2000;18:208-216.

Richter JE, Falk GW. Barrett's esophagus and adenocarcinoma. The need for a consensus conference. J Clin Gastroenterol 1996;23:88-90.

Riddell RH, Goldman H, Ransohoff DE, et al. Dysplasia in inflammatory bowel disease. Hum Pathol 1983;14:931-968.

Riegman PH, Burgart LJ, Wang KK, et al. Allelic imbalance of 7q32.3-q36.1 during tumorigenesis in Barrett's esophagus. Cancer Res 2002;62:1531-1533.

Robaszkiewicz M, Hardy E, Volant A, et al. [Flow cytometric analysis of cellular DNA content in Barrett's esophagus. A study of 66 cases]. Gastroenterol Clin Biol 1991;15:703-710.

Romero Y, Cameron AJ, Locke GR 3rd, et al. Familial aggregation of gastro-esophageal reflux in patients with Barrett's esophagus and esophageal adeno-carcinoma. Gastroenterology 1997;113:1449-1456.

Rosenberg JC, Budey H, Edwards RC, et al. Analysis of adenocarcinoma in Barrett's esophagus utilizing a staging system. Cancer 1985;55:1353-1360.

Rugge M, Russo V, Busatto G, et al. The phenotype of gastric mucosa coexisting with Barrett's oesophagus. J Clin Pathol 2001;54:456-460.

Rusch VW, Levine DS, Haggitt R, Reid BJ. The management of high grade dys-plasia and early cancer in Barrett's esophagus. A multidisciplinary problem. Cancer 1994;74:1225-1229.

Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 1998;93:1028-1032.

Sampliner RE. Prevention of adenocarcinoma by reversing Barrett's esophagus with mucosal ablation. World J Surg 2003;27:1026-1029.

Sampliner RE. Reduction of acid exposure and regression of Barrett's esophagus. Dig Dis 2000;18:203-207.

Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002;97:1888-1895.

Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high grade dysplasia. Gastroenterology 2001;120:1607-1619.

Sharma P. An update on strategies for eradication of Barrett's mucosa. Am J Med 2001b;111 Suppl 8A:147S-152S.

Sharma P. Controversies in Barrett's esophagus: management of high grade dys-plasia. Semin Gastrointest Dis 2001a;12:26-32.

Sharma P, Topalovski M, Mayo MS, Weston AP. Methylene blue chromoendoscopy for detection of short segment Barrett's esophagus. Gastrointest Endosc 2001;54: 289-293.

Shirvani V, Ouatu-Lascar R, Kaur B, et al. Cyclooxygenase-2 expression in Barrett's esophagus and adenocarcinoma. Ex vivo induction by bile salts and acid exposure. Gastroenterology 2000;118:487-496.

Sinicrope FA, Gill S. Role of cylcooxygenase-2 in colorectal cancer. Cancer Metastasis Rev 2004;23:63-75.

Skinner DB, Walther BC, Riddell RH, et al. Barrett's esophagus. Comparison of benign and malignant cases. Ann Surg 1983;198:554-565.

Smith RRL, Hamilton SR, Boitnott JK, et al. The spectrum of carcinoma arising in Barrett's esophagus. Am J Surg Pathol 1984;8:563-573.

Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000;60:5767-5772.

Souza RF, Shewmake K, Terada LS, Spechler SJ. Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. Gastroenterology 2002;122:299-307.

Spechler SJ. Barrett's esophagus. Gastroenterologist 1994;2:273-284.

Spechler SJ. Screening and surveillance for complications related to gastroesophageal reflux disease. Am J Med 2001;111 Suppl 8A:130S-136S.

Spechler SJ. Short and ultrashort Barrett's esophagus—what does it mean? Semin Gastrointest Dis 1997;8:59-67.

Spechler SJ, Zeroogian JM, Antonioli DA. Prevalence of metaplasia at the gastroesophageal junction. Lancet 1994;92:414-418.

Streitz JM, Andrews CW, Ellis FH. Endoscopic surveillance of Barrett's esophagus. J Thorac Cardiovasc Surg 1993;105:383-388.

Tseng EE, Wu TT, Yeo CJ, Heitmiller RF. Barrett's esophagus with high grade dysplasia: surgical results and long-term outcome—an update. J Gastrointest Surg 2003;7:164-170.

Vaezi MF, Falk GW, Peek RM, et al. CagA-positive strains of Helicobacter pylori may protect against Barrett's esophagus. Am J Gastroenterol 2000;95:2206-2211.

Vaezi MF, Richter JE. Synergism of acid and duodenogastroesophageal reflux in complicated Barrett's esophagus. Surgery 1995;117:699-704.

VanderBurgh A, Dees J, Hop WCI, et al. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996;139:5-8.

vanSandick J, vanLanschot J, Kuiken B, et al. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998;43:216-222.

Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 2002;99:860-868.

Wang HH, Sovie S, Zeroogian JM, et al. Value of cytology in detecting intestinal metaplasia and associated dysplasia at the gastroesophageal junction. Hum Pathol 1997;28:465-471.

Wang KK. Photodynamic therapy of Barrett's esophagus. Gastrointest Endosc Clin N Am 2000;10:409-419.

Wang KK, Sampliner RE. Mucosal ablation therapy of Barrett esophagus. Mayo Clin Proc 2001;76:433-437.

Wilson K, Fu S, Ramanujam K, et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adeno-carcinoma. Cancer Res 1998;58:2929-2934.

Wong DJ, Paulson TG, Prevo LJ, et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001;61:8284-8289.

Wu TT, Watanabe T, Heitmiller R, et al. Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am J Pathol 1998;153:287-294.

Zimmerman K, Sarbia M, Weber A, et al. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59:198-204.

Zwas F, Shields HM, Doos WG, et al. Scanning electron microscopy of Barrett's epithelial and its correlation with light microscopy and mucin stains. Gastroenterology 1986;90:1932-1941.

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment